Cargando…
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
Dual orexin receptor antagonists (DORAs) represent a novel type of sleep medication that provide an alternative to the traditionally used positive allosteric gamma-aminobutyric acid (GABA)-A receptor modulators. Daridorexant is a new DORA that exhibited in phase 3 trials in insomnia not only a benef...
Autores principales: | Roch, Catherine, Bergamini, Giorgio, Steiner, Michel A., Clozel, Martine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455402/ https://www.ncbi.nlm.nih.gov/pubmed/34415378 http://dx.doi.org/10.1007/s00213-021-05954-0 |
Ejemplares similares
-
Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
por: Sarathi Chakraborty, Dwaipayan, et al.
Publicado: (2023) -
A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
por: Ziemichód, Wojciech, et al.
Publicado: (2022) -
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021) -
Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022) -
Orexin receptor antagonists as therapeutic agents for insomnia
por: Equihua, Ana C., et al.
Publicado: (2013)